Benigno Rodriguez1, David M Asmuth, Roy M Matining, John Spritzler, Jeffrey M Jacobson, Robbie B Mailliard, Xiao-Dong Li, Ana I Martinez, Allan R Tenorio, Franco Lori, Julianna Lisziewicz, Suria Yesmin, Charles R Rinaldo, Richard B Pollard. 1. *Division of Infectious Diseases and Center for AIDS Research, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH; †Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA; ‡Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA; §Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA; ‖University of Pittsburgh, Pittsburgh, PA; ¶Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD; #Department of Medicine, Rush University Medical Center, Chicago, IL; **ViroStatics srl, Sassari, Italy; ††Genetic Immunity, Budapest, Hungary; ‡‡Genetic Immunity, McLean, VA; and §§Social & Scientific Systems, Inc, Silver Spring, MD.
Abstract
BACKGROUND: HIV-specific cellular immune responses are associated with control of viremia and delayed disease progression. An effective therapeutic vaccine could mimic these effects and reduce the need for continued antiretroviral therapy. DermaVir, a topically administered plasmid DNA-nanomedicine expressing HIV (CladeB) virus-like particles consisting of 15 antigens, induces predominantly central memory T-cell responses. METHODS:Treated HIV-infected adults (HIV RNA <50 and CD4 >350) were randomized to placebo or escalating DermaVir doses (0.1 or 0.4 mg of plasmid DNA at weeks 1, 7, and 13 in the low- and intermediate-dose groups and 0.8 mg at weeks 0, 1, 6, 7, 12, and 13 in the high-dose group), n = 5-6 evaluable subjects per group. Immunogenicity was assessed by a 12-day cultured interferon-γ enzyme-linked immunosorbent spot assay at baseline and at weeks 9, 17, and 37 using 1 Tat/Rev and 3 overlapping Gag peptide pools (p17, p24, and p15). RESULTS: Groups were comparable at baseline. The study intervention was well tolerated, without dose-limiting toxicities. Most responses were highest at week 17 (4 weeks after last vaccination) when Gag p24 responses were significantly greater among intermediate-dose group compared with control subjects [median (IQR): 67,600 (5633-74,368) versus 1194 (9-1667)] net spot-forming units per million cells, P = 0.032. In the intermediate-dose group, there was also a marginal Gag p15 response increase from baseline to week 17 [2859 (1867-56,933), P = 0.06], and this change was significantly greater than in the placebo group [0 (-713 to 297), P = 0.016]. CONCLUSIONS: DermaVir administration was associated with a trend toward greater HIV-specific, predominantly central memory T-cell responses. The intermediate DermaVir dose tended to show the greatest immunogenicity, consistent with previous studies in different HIV-infected patient populations.
RCT Entities:
BACKGROUND: HIV-specific cellular immune responses are associated with control of viremia and delayed disease progression. An effective therapeutic vaccine could mimic these effects and reduce the need for continued antiretroviral therapy. DermaVir, a topically administered plasmid DNA-nanomedicine expressing HIV (CladeB) virus-like particles consisting of 15 antigens, induces predominantly central memory T-cell responses. METHODS: Treated HIV-infected adults (HIV RNA <50 and CD4 >350) were randomized to placebo or escalating DermaVir doses (0.1 or 0.4 mg of plasmid DNA at weeks 1, 7, and 13 in the low- and intermediate-dose groups and 0.8 mg at weeks 0, 1, 6, 7, 12, and 13 in the high-dose group), n = 5-6 evaluable subjects per group. Immunogenicity was assessed by a 12-day cultured interferon-γ enzyme-linked immunosorbent spot assay at baseline and at weeks 9, 17, and 37 using 1 Tat/Rev and 3 overlapping Gag peptide pools (p17, p24, and p15). RESULTS: Groups were comparable at baseline. The study intervention was well tolerated, without dose-limiting toxicities. Most responses were highest at week 17 (4 weeks after last vaccination) when Gagp24 responses were significantly greater among intermediate-dose group compared with control subjects [median (IQR): 67,600 (5633-74,368) versus 1194 (9-1667)] net spot-forming units per million cells, P = 0.032. In the intermediate-dose group, there was also a marginal Gagp15 response increase from baseline to week 17 [2859 (1867-56,933), P = 0.06], and this change was significantly greater than in the placebo group [0 (-713 to 297), P = 0.016]. CONCLUSIONS: DermaVir administration was associated with a trend toward greater HIV-specific, predominantly central memory T-cell responses. The intermediate DermaVir dose tended to show the greatest immunogenicity, consistent with previous studies in different HIV-infectedpatient populations.
Authors: Jacqueline Neuhaus; David R Jacobs; Jason V Baker; Alexandra Calmy; Daniel Duprez; Alberto La Rosa; Lewis H Kuller; Sarah L Pett; Matti Ristola; Michael J Ross; Michael G Shlipak; Russell Tracy; James D Neaton Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: Warren L Dinges; Julia Richardt; David Friedrich; Emilie Jalbert; Yi Liu; Claire E Stevens; Janine Maenza; Ann C Collier; Daniel E Geraghty; Jeremy Smith; Zoe Moodie; James I Mullins; M Juliana McElrath; Helen Horton Journal: J Virol Date: 2010-02-10 Impact factor: 5.103
Authors: Moupali Das; Priscilla Lee Chu; Glenn-Milo Santos; Susan Scheer; Eric Vittinghoff; Willi McFarland; Grant N Colfax Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240
Authors: Stephen M Todryk; Ansar A Pathan; Sheila Keating; David W Porter; Tamara Berthoud; Fiona Thompson; Paul Klenerman; Adrian V S Hill Journal: Immunology Date: 2009-09 Impact factor: 7.397
Authors: Henrik Kloverpris; Ingrid Karlsson; Jesper Bonde; Mette Thorn; Lasse Vinner; Anders E Pedersen; Julie L Hentze; Betina S Andresen; Inge M Svane; Jan Gerstoft; Gitte Kronborg; Anders Fomsgaard Journal: AIDS Date: 2009-07-17 Impact factor: 4.177
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Perla Abigail Alvarado-Vazquez; Laura Bernal; Candler A Paige; Rachel L Grosick; Carolina Moracho Vilrriales; David Wilson Ferreira; Cristina Ulecia-Morón; E Alfonso Romero-Sandoval Journal: Immunobiology Date: 2017-05-16 Impact factor: 3.144
Authors: Laura Bernal; Abigail Alvarado-Vázquez; David Wilson Ferreira; Candler A Paige; Cristina Ulecia-Morón; Bailey Hill; Marina Caesar; E Alfonso Romero-Sandoval Journal: Immunobiology Date: 2016-09-05 Impact factor: 3.144
Authors: E R Tőke; O Lőrincz; Z Csiszovszki; E Somogyi; G Felföldi; L Molnár; R Szipőcs; A Kolonics; B Malissen; F Lori; J Trocio; N Bakare; F Horkay; N Romani; C H Tripp; P Stoitzner; J Lisziewicz Journal: Gene Ther Date: 2014-04-03 Impact factor: 5.250
Authors: Paolo Palma; Lindvi Gudmundsdotter; Andrea Finocchi; Lars E Eriksson; Nadia Mora; Veronica Santilli; Angela Aquilani; Emma C Manno; Paola Zangari; Maria Luisa Romiti; Carla Montesano; Alba Grifoni; Andreas Brave; Karl Ljungberg; Pontus Blomberg; Stefania Bernardi; Eric Sandström; Bo Hejdeman; Paolo Rossi; Britta Wahren Journal: Vaccines (Basel) Date: 2014-07-17